Overview

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

130-nm albumin-bound paclitaxel
Cetuximab
Gemcitabine
pembrolizumab